SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., a company dedicated to developing innovative medicines for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 clinical trial of its lead compound, CAL-101, a small molecule phosphoinositide-3 kinase (PI3K) delta inhibitor, in patients with hematologic cancer.
